

=> b reg
 FILE 'REGISTRY' ENTERED AT 09:31:58 ON 09 NOV 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2007 HIGHEST RN 952702-46-4
 DICTIONARY FILE UPDATES: 8 NOV 2007 HIGHEST RN 952702-46-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> d que sta l6
 L2 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 GG CAT IS UNS AT 5
 DEFAULT ECLEVEL IS LIMITED
 ECOUNT IS E8 C E1 N AT 10

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 10

STEREO ATTRIBUTES: NONE
 L4 1182088 SEA FILE=REGISTRY ABB=ON PLU=ON NC4-C6/ES
 L6 345 SEA FILE=REGISTRY SUB=L4 SSS FUL L2

100.0% PROCESSED 249614 ITERATIONS 345 ANSWERS
 SEARCH TIME: 00.00.17

=> b hcap
 FILE 'HCAPLUS' ENTERED AT 09:32:22 ON 09 NOV 2007
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
 held by the publishers listed in the PUBLISHER (PB) field (available
 for records published or updated in Chemical Abstracts after December
 26, 1996), unless otherwise indicated in the original publications.
 The CA Lexicon is the copyrighted intellectual property of the
 the American Chemical Society and is provided to assist you in searching
 databases on STN. Any dissemination, distribution, copying, or storing
 of this information, without the prior written consent of CAS, is
 strictly prohibited.

FILE COVERS 1907 - 9 Nov 2007 VOL 147 ISS 21
FILE LAST UPDATED: 8 Nov 2007 (20071108/ED)


New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> d bib abs hitrn fhitrn l11 tot

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 AN 2004:45183 HCAPLUS
 DN 141:23903
 TI Preparation of indole amino acid derivatives as somatostatin agonists or antagonists
 IN Abe, Hidenori; Matsunaga, Shinichi; Takekawa, Shiro; Watanabe, Masanori
 PA Takeda Chemical Industries, Ltd., Japan
 SO PCT Int. Appl., 482 pp.
 COEN: PXX02
 DT Patent
 LA English
 FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2004046107	A1	20040603	2003WO-JP14622	20031118
WO2004046107	AB	20050616		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CE, DE, DK, DM, DE, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, ME, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TR, TT, TZ, UA, UG, US, VC, VM, YU, ZA, ZM, ZW				
RW: BW, CH, CM, KE, LS, MM, NE, SD, SE, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KE, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CE, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GO, GM, ML, MR, NE, SN, TD, TG				
CA-----2506735	A1	20040603	2003CA-2506735	20031118
AU2003280838	A1	20040615	2003AU-0280838	20031118
JP2004300133	A1	20041028	2003JP-0388524	20031118
EP-----1462898	A1	20050817	2003EP-0772841	20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN-----1738798	A	20060222	CN 2003-8010833	20031118
US2006223826	A	20061005	2005US-0534725	20050512
2002JP-0335661	A	20021119		
2003JP-0076435	A	20030319		
2003WO-JP14622	W	20031118		
GI MARPAT 141:23903				




I

AB The invention relates to compds. $Z-Y-N(Ya-Za)CH(CR4SR6)CONR3-A-B-NR1R2$ [A is an aromatic ring optionally having substituents; B, Y and Ya are a bond or spacer; R1, R2 are H, (un)substituted hydrocarbyl or heterocyclyl or R1R2N is a ring or forms a ring with ring A; R3 is H, (un)substituted hydrocarbyl or heterocyclyl; R4, R5 are H or (un)substituted hydrocarbyl or form a ring; R6 is (un)substituted indolyl; Z, Za are H, halo or a

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 cyclic group) or their salts or prodrugs having somatostatin receptor binding inhibition activity. Thus, 2-aminobutanamide deriv. I was prepd. via amidation of (2R,3S)-3-[(1H-indol-3-yl)-2-[[4-phenyl-1-piperidinyl]carbonyl]amino]butanoic acid with 3-[[dimethylamino)methyl]aniline dihydrochloride.
 IT 697310-48-BP
 RL: BTP (Byproduct); PREP (Preparation)
 (preparation of indole amino acid derivs. as somatostatin agonists or antagonists)
 IT 697307-06-SP 697307-07-6P 697307-08-7P
 697307-10-1P 697307-12-3P 697307-14-5P
 697307-15-6P 697307-33-8P 697308-37-5P
 697308-38-6P 697308-39-7P 697309-91-4P
 697309-93-6P 697309-96-9P 697309-97-0P
 697309-99-2P 697310-20-6P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indole amino acid derivs. as somatostatin agonists or antagonists)
 IT 697307-16-7P 697307-17-8P 697307-18-9P
 697307-19-0P 697307-20-3P 697307-21-4P
 697307-22-5P 697307-23-6P 697307-24-7P
 697307-25-8P 697307-26-9P 697307-27-0P
 697307-28-1P 697307-29-2P 697307-30-5P
 697307-31-6P 697307-32-7P 697307-37-2P
 697307-38-3P 697307-39-4P 697307-40-7P
 697307-41-8P 697307-42-9P 697307-45-5P
 697307-46-3P 697307-47-4P 697307-49-6P
 697307-50-9P 697307-51-0P 697307-52-1P
 697307-53-2P 697307-54-3P 697307-55-4P
 697307-56-5P 697307-57-6P 697307-58-7P
 697307-59-8P 697307-60-1P 697307-61-2P
 697307-62-3P 697307-63-4P 697307-64-5P
 697307-65-6P 697307-66-7P 697307-67-8P
 697307-68-9P 697307-69-0P 697307-70-3P
 697307-71-4P 697307-72-5P 697307-73-6P
 697307-74-7P 697307-75-8P 697307-76-9P
 697307-77-0P 697307-78-1P 697307-78-2P
 697307-80-5P 697307-81-6P 697307-82-7P
 697307-83-8P 697307-84-9P 697307-85-0P
 697307-86-1P 697307-87-2P 697307-88-3P
 697307-89-4P 697307-90-7P 697307-91-8P
 697307-92-9P 697307-93-0P 697307-94-1P
 697307-95-2P 697307-96-3P 697307-97-4P
 697307-98-5P 697307-99-6P 697308-00-2P
 697308-01-3P 697308-02-4P 697308-03-5P
 697308-04-6P 697308-11-5P 697308-12-6P
 697308-13-7P 697308-14-8P 697308-15-9P
 697308-30-8P 697308-31-9P 697308-32-0P
 697308-33-1P 697308-34-2P 697308-35-3P
 697308-36-4P 697308-40-0P 697308-41-1P
 697308-42-2P 697308-44-4P 697308-45-5P
 697308-46-6P 697308-47-7P 697308-48-8P
 697308-49-9P 697308-50-2P 697308-51-3P
 697308-52-4P 697308-53-5P 697308-54-6P
 697308-55-7P 697308-56-8P 697308-57-9P
 697308-58-0P 697308-59-1P 697308-60-4P
 697308-61-5P 697308-62-6P 697308-63-7P
 697308-64-8P 697308-65-9P 697308-66-0P
 697308-67-1P 697308-68-2P 697308-69-3P
 697308-70-6P 697308-71-7P 697308-72-8P
 697308-73-9P 697308-74-0P 697308-75-1P
 697308-76-2P 697308-77-3P 697308-78-4P
 697308-79-5P 697308-80-8P 697308-81-9P
 697308-82-0P 697308-83-1P 697308-84-2P
 697308-85-3P 697308-86-4P 697308-87-5P
 697308-88-6P 697308-89-7P 697308-90-0P
 697308-91-1P 697308-92-2P 697308-93-3P
 697308-94-4P 697308-95-5P 697308-96-6P

L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L11 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2007 ACS on STN (Continued)

697308-97-7P 697308-98-8P 697308-99-9P
 697309-00-5P 697309-01-6P 697309-02-7P
 697309-03-8P 697309-04-9P 697309-05-0P
 697309-06-1P 697309-07-2P 697309-08-3P
 697309-09-4P 697309-10-7P 697309-11-8P
 697309-12-9P 697309-13-0P 697309-14-1P
 697309-15-2P 697309-16-3P 697309-17-4P
 697309-18-5P 697309-19-6P 697309-20-9P
 697309-21-0P 697309-22-1P 697309-23-2P
 697309-24-3P 697309-25-4P 697309-26-5P
 697309-27-6P 697309-28-7P 697309-30-1P
 697309-31-2P 697309-32-3P 697309-33-4P
 697309-34-5P 697309-35-6P 697309-36-7P
 697309-37-8P 697309-38-9P 697309-39-0P
 697309-40-3P 697309-41-4P 697309-42-5P
 697309-43-6P 697309-44-7P 697309-45-8P
 697309-46-9P 697309-47-0P 697309-48-1P
 697309-50-5P 697309-51-6P 697309-52-7P
 697309-53-8P 697309-54-9P 697309-55-0P
 697309-56-1P 697309-57-2P 697309-58-3P
 697309-59-4P 697309-60-7P 697309-61-8P
 697309-62-9P 697309-70-9P 697309-71-0P
 697309-72-1P 697309-73-2P 697309-74-3P
 697309-75-4P 697309-76-5P 697309-77-6P
 697309-78-7P 697309-80-1P 697309-82-3P
 697309-84-5P 697309-86-7P 697309-88-9P
 697309-90-3P 697309-92-5P 697309-94-7P
 697309-95-8P 697309-98-1P 697310-00-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of indole amino acid derivs. as somatostatin agonists or antagonists)

IT 697310-01-3P 697310-02-4P 697310-03-5P
 697310-04-6P 697310-05-7P 697310-06-8P
 697310-07-9P 697310-08-0P 697310-09-1P
 697310-10-4P 697310-11-5P 697310-12-6P
 697310-13-7P 697310-14-8P 697310-15-9P
 697310-16-0P 697310-17-1P 697310-18-2P
 697310-19-3P 697310-21-7P 697310-22-8P
 697310-23-9P 697310-24-0P 697310-25-1P
 697310-28-4P 697310-30-8P 697310-32-0P
 697310-33-1P 697310-34-2P 697310-35-3P
 697310-36-4P 697310-37-5P 697310-39-7P
 697310-40-0P 697310-41-1P 697310-42-2P
 697310-43-3P 697310-44-4P 697310-45-5P
 697310-46-6P 697310-47-7P 697310-49-9P
 697310-50-2P 697310-52-4P 697310-60-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole amino acid derivs. as somatostatin agonists or antagonists)

IT 697307-11-2
 RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of indole amino acid derivs. as somatostatin agonists or antagonists)

IT 697307-09-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of indole amino acid derivs. as somatostatin agonists or antagonists)

IT 697310-48-BP
 RL: BTP (Byproduct); PREP (Preparation)

(preparation of indole amino acid derivs. as somatostatin agonists or antagonists)

RN 697310-48-8 HCAPLUS
 CN 1H-Indole-3-propanamide, α -[[4-(4-acetyl-1-piperidinyl)carbonyl]amino]-N-[5-[[dimethylamino)methyl]-2-ethoxyphenyl]- β -methyl-, (or, β S)- (CA INDEX NAME)

Absolute stereochemistry.

=> d bib abs hitstr 120 tot

L20 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2007 ACS on SIN
AN 2001:33128 HCAPLUS
DN 134:326766
TI Preparation of amino acid derivatives of aminobenzoic and
aminobiphenylcarboxylic acids as anti-cancer agents
IN Blood, Christine H.; Neustadt, Bernard R.; Smith, Elizabeth M.
PA Schering Corporation, USA
SO U.S., 29 pp.
CODEN: USKXAM
DT Patent
LA English
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-6228985	B1	20010508	1998US-0082787	19980521 <--
PRAI 1998US-0082787		19980521	<--	
OS MARDAT 134:326766				

AB Compds. Q-NH(CH₂)_nC₆H₄C₆H₄CO-R or Q-NH(CH₂)_nC₆H₄CO-R [n is 0 or 1; R is NH₂ or NHC(H)R₂, where R₁, R₂ = H, alkyl, aralkyl, heteroaralkyl, carboxy, carboxyalkyl, carbamoyl; Q is R₃(O) or R₄CONHC(H)R₅CO, where R₅ = H, alkyl, aralkyl, heteroaralkyl, carbamoylalkyl; R₃, R₄ = H, alkyl, alkoxy, arylalkoxy, aralkyl, heteroaralkyl, carbamoylalkyl (substituents in the biphenylcarboxylic and benzoic acids may not be in ortho, ortho'- and ortho-positions, resp.) or biolabile esters or pharmaceutically acceptable salts were prepared. The compds. are useful for treating urokinase-type plasminogen activator (uPA) or urokinase-type plasminogen activator receptor (uPAR)-mediated disorders, e.g., tumor metastasis, tumor angiogenesis, restenosis, chronic inflammation, or corneal angiogenesis. Thus, N-[4-[(4-[(3-indolylacetyl)amino]phenyl)benzoyl]-L-phenylalanine was prepared by the solid-phase method and showed IC₅₀ = 20 nM for binding of radioligand C-[125I]-Tyr241-ATP.

IT 336103-45-8P
RL: BNC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USBS (Uses) (preparation of amino acid derivs. of aminobenzoic and aminobiphenylcarboxylic acids as anti-cancer agents)

RN 336103-45-8 HCAPLUS
CN 1-Phenylalanine, N-acetyl-L-tryptophyl-4-aminobenzoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L20 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on SIN
AN 1966:473524 HCAPLUS
DN 65:73524
OREF 65:13719h, 13720a-b
TI 6-[o-(Aminoacylamido)benzamidolpenicillanic acids
IN Alburn, Harvey E.; Grant, Norman H.
PA American Home Products Corp.
SO 3 pp.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US-3268515		19660823	1964US-0358066	19640407 <--
PRAI US 19640407		<--		

AB 6-[o-(Aminobenzamidolpenicillanic acid (I) and derivs. of I are treated with an N-carboxy amino acid anhydride to give the title acids; useful as antibacterials. A mixture of 404 mg. I, 212 mg. D-phenylglycine-N-carboxy anhydride, and 30 ml. cold water is agitated 60 min. at 1-2° and pH 6.0 to give 6-[o-(2-amino-2-phenylacetamidolbenzamidolpenicillanic acid. Similarly prepared are the following penicillanic acids:
6-[2-(D-2-amino-4-methylvaleramido)-5-nitrobenzamidol;
6-[2-(2-amino-2-phenylacetamidol)-3-naphthamidol]; 6-[N-methyl-2-(2-amino-2-phenylacetamidol)-5-nitrobenzamidol]; 6-[2-(2-amino-5-methylbenzamidolbenzamidol]; 6-[2-(2-pyrrolidinedicarboxamidolbenzamidol]; 6-[2-(L-2-aminopropionamidolbenzamidol]; 6-[2-(D-2-amino-2-phenylacetamidol)-5-nitrobenzamidol]; 6-[2-(L-2-amino-3-phenylpropionamidol)-5-nitrobenzamidol]; 6-[2-(1-aminocyclobutanecarboxamidol)-5-nitrobenzamidol]; 6-[2-(1-aminocyclopentanecarboxamidol)-5-nitrobenzamidol]; 6-[2-(1-aminocyclohexanecarboxamidol)-5-nitrobenzamidol]; 6-[2-(1-aminocyclooctanecarboxamidol)-5-nitrobenzamidol]; 6-[2-(o-aminobenzamidol)-5-nitrobenzamidol]; 6-[2-(2-amino-5-nitrobenzamidol)-5-nitrobenzamidol]; 6-[2-(2-amino-5-methylbenzamidol)-5-nitrobenzamidol]; 6-[2-(2-amino-5-methylbenzamidol)-5-nitrobenzamidol]; 6-[2-(D-2-amino-5-methylbenzamidol)-5-nitrobenzamidol]; and 6-[2-(L-2-aminoindole-3-propionamidol)-5-nitrobenzamidol].
10502-80-4 10502-81-5 102264-37-9
(Derived from data in the 7th Collective Formula Index (1962-1966))

RN 10502-80-4 HCAPLUS
CN 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-amino-3-indol-3-ylpropionamidol)-5-nitrobenzamidol]-3,3-dimethyl-7-oxo- (8CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 10502-81-5 HCAPLUS
CN 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-amino-3-indol-3-ylpropionamidol)-5-nitrobenzamidol]-3,3-dimethyl-7-oxo- (8CI) (CA INDEX NAME)

Absolute stereochemistry.

L20 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2007 ACS on SIN
AN 1966:473525 HCAPLUS
DN 65:73525
OREF 65:13720b-e
TI Penicillins
IN Jansen, Alexander B. A.; Stokes, Peter J.
PA John Wyeth & Brother Ltd.
SO 4 pp.
DT Patent
LA Unavailable
FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB-1034874		19660706	1964GB-0009025	19640303 <--
PRAI GB 19640303		<--		

GI For diagram(s), see printed CA issue.
AB A series of penicillins (I) were synthesized by treating a ketene dimer (II) with 6-amino-penicillanic acid or its salt. For example, a solution of 0.01 mole ketene dimer in 6 ml. tetrahydrofuran (THF) was added gradually with stirring to an ice-cooled solution of 6-aminopenicillanic acid (0.01 mole) in a mixture of 5 ml. water and 10 ml. THF containing 0.02 mole Et₃N. Stirring was continued for another hr.; water was added and the mixture extracted with ether. The aqueous layer was acidified and the liberated acid collected in ether. The addition of 2N butanolic K 2-ethylhexanoate (0.01 equivalent) to the dried solution afforded the K salt as a gum which was obtained as a solid by solution in 3 ml. acetone followed by reprecipitation with dry ether and trituration with fresh dry ether. The product was separated by centrifugation. In the reactions in which CH₂Cl₂ was used as the solvent, 2 equivalent of Et₃N was used; the solution was prepared as described by Perron, et al. (CA 56, 11579d). In this case, the solvent was removed in vacuo at room temperature before the reaction mixture was worked up. 1, R₂, solvent, 4 yield, [α]_D²⁵, [c in H₂O]; H, H, aqueous THF, 27-39, 271°, 0.8; Me, H, aqueous THF, 32-42, 290°, 1.1; Et, H, aqueous THF, 42, 292°, 1.2; Pr, H, (CH₂Cl₂, 13-18, 257°, 0.9; iso-Pr, H, CH₂Cl₂, 34-7, 235°, 0.4; Bu, H, CH₂Cl₂, 30 204°, 1.9; Ph, H, aqueous THF, 44, 260°, 0.9; Me, Me, aqueous THF, 6-25, 263°, 0.7. The K salts of penicillin prepared are given in the table.

IT 102264-37-9
(Derived from data in the 7th Collective Formula Index (1962-1966))


RN 102264-37-9 HCAPLUS
CN 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[(2-amino-3-(1H-indol-3-yl)-1-oxopropyl)amino]-5-nitrobenzoyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2S,5S,6R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.

L20 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2007 ACS on SIN (Continued)




RN 102264-37-9 HCAPLUS
CN 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-[(2-amino-3-(1H-indol-3-yl)-1-oxopropyl)amino]-5-nitrobenzoyl]amino]-3,3-dimethyl-7-oxo-, [2S-(2S,5S,6R)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 909884-10-2P, 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-amino-3-indol-3-ylpropionamidol)-5-nitrobenzamidol]-3,3-dimethyl-7-oxo-, D- (preparation of)
RL: PREP (Preparation)
RN 909884-10-2 HCAPLUS
CN 4-Thia-1-arabicyclo[3.2.0]heptane-2-carboxylic acid, 6-[2-(2-amino-3-indol-3-ylpropionamidol)-5-nitrobenzamidol]-3,3-dimethyl-7-oxo-, D- (7CI) (CA INDEX NAME)



=> d his

```

(FILE 'HOME' ENTERED AT 08:30:48 ON 09 NOV 2007)
FILE 'REGISTRY' ENTERED AT 08:30:58 ON 09 NOV 2007
L1      STR
      FILE 'REGISTRY' ENTERED AT 08:40:51 ON 09 NOV 2007
L2      STR L1
L3      1 L2
L4      1182088 NC4-C6/ES
L5      1 L2 SAM SUB=L4
L6      345 L2 FULL SUB=L4
      SAV TEM J725C1/A L6
      FILE 'HCAPLUS' ENTERED AT 08:47:25 ON 09 NOV 2007
      FILE 'REGISTRY' ENTERED AT 08:47:42 ON 09 NOV 2007
      FILE 'HCAPLUS' ENTERED AT 08:47:42 ON 09 NOV 2007
      FILE 'REGISTRY' ENTERED AT 08:47:42 ON 09 NOV 2007
      FILE 'HCAPLUS' ENTERED AT 08:53:04 ON 09 NOV 2007
      FILE 'STNGUIDE' ENTERED AT 08:53:12 ON 09 NOV 2007
      FILE 'HCAPLUS' ENTERED AT 08:53:47 ON 09 NOV 2007
L7      1 US20060223826 /PN
      FILE 'REGISTRY' ENTERED AT 08:53:58 ON 09 NOV 2007
      FILE 'HCAPLUS' ENTERED AT 08:54:00 ON 09 NOV 2007
L8      TRA L7 1- RN :      799 TERMS
      FILE 'REGISTRY' ENTERED AT 08:54:00 ON 09 NOV 2007
L9      799 SEA L8
L10     299 L6 AND L9
      FILE 'HCAPLUS' ENTERED AT 08:54:30 ON 09 NOV 2007
L11     1 L10
      FILE 'REGISTRY' ENTERED AT 08:54:52 ON 09 NOV 2007
L12     46 L6 NOT L10
      FILE 'STNGUIDE' ENTERED AT 08:55:27 ON 09 NOV 2007
      FILE 'HCAPLUS' ENTERED AT 09:07:02 ON 09 NOV 2007
L13     20 L12
L14     13 L13 AND (PD<=20021119 OR AD<=20021119 OR PRD<=20021119)
      FILE 'HCAOLD' ENTERED AT 09:07:57 ON 09 NOV 2007
L15     2 L6
      SEL HIT RN
      FILE 'REGISTRY' ENTERED AT 09:08:18 ON 09 NOV 2007
L16     3 E1-3
      FILE 'HCAPLUS' ENTERED AT 09:08:42 ON 09 NOV 2007
      SEL HIT RN L14
      FILE 'REGISTRY' ENTERED AT 09:08:56 ON 09 NOV 2007
L17     27 E4-30
      FILE 'STNGUIDE' ENTERED AT 09:09:15 ON 09 NOV 2007
      FILE 'REGISTRY' ENTERED AT 09:26:27 ON 09 NOV 2007
L18     5 L17 AND (C29H28N4O5 OR C26H26N6O7S)

```

FILE 'HCAPLUS' ENTERED AT 09:28:32 ON 09 NOV 2007
L19 3 L18
L20 3 L19 AND L14

FILE 'REGISTRY' ENTERED AT 09:31:58 ON 09 NOV 2007

FILE 'HCAPLUS' ENTERED AT 09:32:22 ON 09 NOV 2007

=>